Initial drug resistance and tuberculosis treatment outcomes: Systematic review and meta-analysis

Annals of Internal Medicine

Volumn 149, Issue 2, 2008, Pages 123-134

  Lew, Woojin ^a,b   Pai, Madhukar ^a   Oxlade, Olivia ^a   Martin, Daniel ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Korean Institute of Tuberculosis   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AUTHOR; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; EMBASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG TUBERCULOSIS; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; DRUG EFFECT; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 47549102958     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-2-200807150-00008     Document Type: Review

References (72)

1. Pyle MM. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin. 1947;22:465-73.
2. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002;295:2042-6. [PMID: 11896268]
3. Aziz MA, Wright A, Laszlo A, De MA, Portaels F, Van DA et al. WHO/ International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142-54. [PMID: 17174706]
4. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194:479-85. [PMID: 16845631]
5. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-5. [PMID: 16557213]
6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. [PMID: 17084757]
7. Caminero JA, World Health Organization, American Thoracic Society, British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis. 2006;10:829-37. [PMID: 16898365]
8. Espinal M, Frieden TR. What are the causes of drug-resistant tuberculosis? In: Frieden TR, ed. Toman's Tuberculosis: Case Detection, Treatment, and Monitoring. Questions and Answers. 2nd ed. Geneva: World Health Organization; 2004:207-8.
9. Toman K. How does drug resistance develop? In: Frieden TR, ed. Toman's Tuberculosis: Case Detection, Treatment, and Monitoring. Questions and Answers. 2nd ed. Geneva: World Health Organization; 2004:193-94.
10. Boulahbal F, Heifets L. Bacteriology of tuberculosis. In: Raviglione M, ed. Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach. 3rd ed. New York: Informa Healthcare USA; 2006:29-46.
11. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969;41:21-43. [PMID: 5309084]
12. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization; 2003:1-108.
13. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006;6:710-25. [PMID: 17067920]
14. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62. [PMID: 12588714]
15. World Health Organization. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001;5:213-5. [PMID: 11326818]
16. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. [PMID: 16836745]
17. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321-59. [PMID: 10070677]
18. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990;112:407-15. [PMID: 2106816]
19. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159:733-40. [PMID: 10051244]
20. Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance - same strain or reinfection? Trans R Soc Trop Med Hyg. 2000;94:603-7. [PMID: 11198641]
21. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis. 2000;4:433-40. [PMID: 10815737]
22. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004;39:1321-8. [PMID: 15494909]
23. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004;170:561-6. [PMID: 15184210]
24. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38:731-6. [PMID: 14986259]
25. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1977;116:3-8. [PMID: 69411]
26. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet. 1974;2:237-40. [PMID: 4135686]
27. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet. 1973;1: 1331-8. [PMID: 4122738]
28. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;1:1079-85. [PMID: 4112569]
29. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1974;2:1100-6. [PMID: 4139405]
30. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study. Am Rev Respir Dis. 1976;114:471-5. [PMID: 788570]
31. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis. 1978;118:219-28. [PMID: 100029]
32. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle. 1979;60:201-10. [PMID: 396701]
33. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. Tubercle. 1980;61:59-69. [PMID: 6159711]
34. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis. 1978;118:39-48. [PMID: 79319]
35. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1986;133:779-83. [PMID: 2871788]
36. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle. 1981;62:95-102. [PMID: 7029838]
37. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1979;119:579-85. [PMID: 375787]
38. Zierski M, Bek E, Long MW, Snider DE Jr. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis. 1981;124:249-51. [PMID: 7283257]
39. Zierski M, Bek E, Long MW, Snider DE Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980;122:879-89. [PMID: 7006476]
40. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. 1987;136:1339-42. [PMID: 2891333]
41. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. Tubercle. 1982;63:89-98. [PMID: 6758252]
42. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 1981;1:171-4. [PMID: 6109855]
43. Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle. 1983;64:153-66. [PMID: 6356538]
44. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle. 1986;67:5-15. [PMID: 3521015]
45. Santha T, Nazareth O, Krishnamurthy MS, Balasubramanian R, Vijayan VK, Janardhanam B, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in south India - 5-year follow up. Tubercle. 1989;70:229-34. [PMID: 2516669]
46. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle. 1983;64:73-91. [PMID: 6351390]
47. Snider DE, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis. 1984;130:1091-4. [PMID: 6508006]
48. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study. Am Rev Respir Dis. 1985;131:727-31. [PMID: 3890640]
49. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1985;132:374-8. [PMID: 2862820]
50. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1988;137:1147-50. [PMID: 2904237]
51. Balasubramanian R, Sivasubramanian S, Vijayan VK, Ramachandran R, Jawahar MS, Paramasivan CN, et al. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle. 1990;71:253-8. [PMID: 2125153]
52. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. Am Rev Respir Dis. 1986;134:27-33. [PMID: 3524334]
53. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1989;139:871-6. [PMID: 2648911]
54. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study. Am Rev Respir Dis. 1989;140:990-5. [PMID: 2508527]
55. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1991;143:262-7. [PMID: 1990938]
56. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. 1991;143:700-6. [PMID: 1901199]
57. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1991;143:707-12. [PMID: 1901200]
58. Zhang LX, Kan G, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Current Therapeutic Research. 1996;57:849-56.
59. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843-7. [PMID: 10359410]
60. Santha T, Rehman F, Mitchison DA, Sarma GR, Reetha AM, Prabhaker R. Tuberculosis Research Centre, Indian Council of Medical Research. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis - a unique approach. Trop Med Int Health. 2004;9:551-8. [PMID: 15117298]
61. Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, Tung LB, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis. 2003;7:631-6. [PMID: 12870683]
62. Yoshiyama T, Yanai H, Rhiengtong D, Palittapongarnpim P, Nampaisan O, Supawitkul S, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis. 2004;8:31-8. [PMID: 14974743]
63. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Tuberculosis Guide for Low Income Countries. 5th ed. Paris: International Union Against Tuberculosis and Lung Disease; 2000.
64. Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin Chest Med. 2005;26:247-71, vi. [PMID: 15837109]
65. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J. 2005;26:339-50. [PMID: 16055883]
66. Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol. 2008;6:41-52. [PMID: 18079742]
67. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007;4:e292. [PMID: 17988168]
68. Global Drug Facility. First-line tuberculosis drugs & formulations currently supplied/to be supplied by the global TB drug facility. World Health Organization. 2003. Accessed at http://stoptb.org/GDF/drugsupply/ drugs.available.html on 3 January 2007.
69. Platt SD, Martin CJ, Hunt SM, Lewis CW. Damp housing, mould growth, and symptomatic health state. BMJ. 1989;298:1673-8. [PMID: 2503174]
70. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83-91. [PMID: 15937767]
71. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis. 2005;9:556-61. [PMID: 15875929]
72. Tripathy SP. [Controlled clinical trial of a 3-month regimen and 2 5-month regimens in the treatment of pulmonary tuberculosis. 2d study of the short-term treatment administered in Madras]. Bull Int Union Tuberc. 1983;58:97-101. [PMID: 6360263]